4-碘-2-甲氧基-1-硝基苯 | 860585-81-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-碘-2-甲氧基-1-硝基苯
• 英文名称: 2-methoxy-4-iodonitrobenzene
• 英文别名: 5-iodo-2-nitro-anisole；5-Jod-2-nitro-anisol；4-Iodo-2-methoxy-1-nitrobenzene
• CAS: 860585-81-5
• 化学式: C₇H₆INO₃
• mdl: MFCD18397934
• 分子量: 279.034
• InChiKey: HIXMWPAZDDJWNC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  55
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-碘-2-甲氧基-1-硝基苯 在 tin(ll) chloride 作用下， 以 乙醇 为溶剂， 反应 4.0h， 以77%的产率得到4-碘-2-甲氧基苯胺
  参考文献：
  名称：

  Discovery of 7-Hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo[b]furan (BNC105), a Tubulin Polymerization Inhibitor with Potent Antiproliferative and Tumor Vascular Disrupting Properties

  摘要：

  A structure activity relationship (SAR) guided design of novel tubulin polymerization inhibitors has resulted in a series of benzo[b]furans with exceptional potency toward cancer cells and activated endothelial cells. The potency of early lead compounds has been substantially improved through the synergistic effect of introducing a conformational bias and additional hydrogen bond donor to the pharmacophore. Screening of a focused library of potent tubulin polymerization inhibitors for selectivity against cancer cells and activated endothelial cells over quiescent endothelial cells has afforded 7-hydroxy-6-methoxy-2-methyl-3-(3,4,5-trimethoxybenzoyl)benzo-[b]furan (BNC105, 8) as a potent and selective antiproliferative. Because of poor solubility, 8 is administered as its disodium phosphate ester prodrug 9 (BNC105P), which is rapidly cleaved in vivo to return the active 8. 9 exhibits both superior vascular disrupting and tumor growth inhibitory properties compared with the benchmark agent combretastatin A-4 disodium phosphate 5 (CA4P).

  DOI：

  10.1021/jm200454y
• 作为产物：
  描述：

  3-碘苯酚 在 sodium nitrate 、 乙醇 、 硫酸 、 sodium carbonate 作用下， 生成 4-碘-2-甲氧基-1-硝基苯
  参考文献：
  名称：

  Hodgson; Moore, Journal of the Chemical Society, 1927, p. 634

  摘要：

  DOI：

文献信息

• [EN] PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS<br/>[FR] DÉRIVÉS PHOSPHORÉS SERVANT D'INHIBITEURS DE KINASE
  申请人：ARIAD PHARMA INC

  公开号：WO2009143389A1

  公开（公告）日：2009-11-26

  The invention features compounds of the general formula (I) in which the variable groups are as defined herein, and to their preparation and use.

  该发明涉及一般式（I）的化合物，其中变量组的定义如本文所述，以及它们的制备和使用。
• Discovery of 5-(4-methylpiperazin-1-yl)-2-nitroaniline derivatives as a new class of SIRT6 inhibitors
  作者：Weining Sun、Xiuli Chen、Shenzhen Huang、Wenpei Li、Chenyu Tian、Shengyong Yang、Linli Li

  DOI：10.1016/j.bmcl.2020.127215

  日期：2020.8

  SIRT6 is a deacetylase of histone H3 and inhibitors of SIRT6 have been thought as potential agents for treatment of diabetes. Herein we report the discovery of a series of new SIRT6 inhibitors containing the skeleton 1-phenylpiperazine. Among them, compound 5-(4-methylpiperazin-1-yl)-2-nitroaniline (6d) is the most potent one, which showed an IC50 value of 4.93 mu M against SIRT6 in the Fluor de Lys (FDL) assay. It displayed K-D values of 9.76 mu M and 10 mu M in surface plasmon resonance (SPR) and isothermal titration calorimetry (ITC) assays, respectively. In selectivity assay, 6d showed no activity against other members of the HDAC family (SIRT1-3 and HDAC1-11) at concentrations up to 200 mu M. In a mouse model of type 2 diabetes, 6d could significantly increase the level of glucose transporter GLUT-1, thereby reducing blood glucose. Overall, this study provides a promising lead compound for subsequent drug discovery targeting SIRT6.
• Hodgson; Handley, Journal of the Chemical Society, 1926, p. 543
  作者：Hodgson、Handley

  DOI：——

  日期：——
• [EN] CHEMICAL COMPOUNDS<br/>[FR] COMPOSÉS CHIMIQUES
  申请人：ASTRAZENECA AB

  公开号：WO2012017239A2

  公开（公告）日：2012-02-09

  The present invention relates to compounds of Formula (I) and/or Formula (Ia): and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds inhibit ALK kinase activity, and thus may be used for the treatment of cancer.